AC Immune to Present at the Jefferies 2023 London Healthcare Conference
- AC Immune to Present at the Jefferies 2023 London Healthcare Conference Lausanne, Switzerland, November 7, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a fireside chat and one-on-one investor meetings during the Jefferies 2023 London Healthcare Conference, taking place in-person in London on November 14-16, 2023. The fireside chat will take place on November 16, 2023, at 6:30 AM (ET) / 11:30 AM (GMT).
- 11/07/2023
|
Is AC Immune (ACIU) Stock Outpacing Its Medical Peers This Year?
- Here is how AC Immune (ACIU) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
- 10/24/2023
|
AC Immune (ACIU) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
- AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/20/2023
|
AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023
- AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will present a corporate overview and participate in one-on-one investor meetings during the Jefferies 2023 CNS & Neuro Summit, taking place in-person in New York City on October 11-12, 2023. AC Immune's corporate presentation will be given in-person with Q&A on Thursday, October 12 at 8:00 AM (EDT) / 2:00 PM (CEST) and will also be accessible via the conference platform.
- 10/05/2023
|
AC Immune (ACIU) Surges 43% in the Past 3 Months: Here's Why
- AC Immune's (ACIU) shares rose 43% over the past three months, driven by rapid progress in the development of its pipeline candidate, ACI-24.060, for neurodegenerative diseases.
- 09/05/2023
|
AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
- AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023
- 09/05/2023
|
AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates
- AC Immune (ACIU) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.24 per share a year ago.
- 08/04/2023
|
AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023
- AC Immune to Present at the B TIG Virtual Biotechnology Conference 2023
- 07/28/2023
|
Why Shares of AC Immune Jumped This Week
- AC Immune is a clinical-stage biotech with 16 programs in its pipeline. It is attempting to develop an Alzheimer's disease vaccine.
- 06/30/2023
|
Trading Penny Stocks With Limited Capital: 3 Tops Tips
- The allure of penny stocks is undeniable. Their low price and potential for massive returns create an inviting landscape for individuals, especially those with limited capital, to take a leap into the world of investing.
- 06/28/2023
|
AC Immune's stock soars 13% after FDA grants fast-track designation to Alzheimer's treatment
- AC Immune SA's stock ACIU, +4.21% soared 13% premarket Tuesday, after the Swiss-based biotech said it has received U.S. Food and Drug Administration fast-track designation for an Alzheimer's disease treatment. The treatment, called ACI-24.060, is an anti-amyloid beta (Abeta) active immunotherapy (vaccine)-candidate.
- 06/27/2023
|
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
- AC Immune at AD/PD ™ 202 3 to Present New Clinical and Preclinical Data f rom its Precision Medicine Pipeline
- 03/20/2023
|
AC Immune: Dementia-Focused Swiss Biotech With A Sad History Of Failures
- ACIU is a leading researcher in the field of dementia, with major deals with big pharma. Unfortunately, AD is a tough space and none of its molecules have turned out well so far.
- 03/18/2023
|
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
- AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
- 03/08/2023
|
AC Immune to Present at the SVB Securities Global Biopharma Conference
- AC Immune to Present at the SVB Securities Global Biopharma Conference
- 02/02/2023
|
Why I've Added A Full Position In AC Immune To My Tax Loss Selling Basket
- ACIU has recently fallen due to what looks like indiscriminate tax loss selling. It now trades at near cash on hand and yet it has numerous programs in clinic and prestigious partners.
- 12/27/2022
|
AC Immune to Present Progress of Alzheimer's Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
- Lausanne, Switzerland, November 2 3 , 202 2 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the upcoming presentations of its vaccine technology SupraAntigen®, and of its anti-Tau and anti-Abeta investigational candidates, at the 15th Clinical Trials on Alzheimer's Disease (CTAD) conference in San Francisco, California (United States) and online, on November 29 – December 2, 2022.
- 11/23/2022
|
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
- AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 07/28/2022
|
AC Immune shares slide 15% premarket after trial of Alzheimer's treatment misses its main goals
- Shares of biotech AC Immune SA ACIU, -9.21% slid 15% in premarket trade Thursday, after the company said a a trial of a treatment for Alzheimer's disease failed to slow or prevent cognitive decline in patients with a specific genetic mutation that causes early-onset disease. The trial involved 252 people who are members of the world's biggest extended family with Autosomal Dominant Alzheimer's Disease, or ADAD, in Colombia.
- 06/16/2022
|
AC Immune to Present at the 2022 Jefferies Healthcare Conference
- LAUSANNE, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor meetings during the 2022 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis hotel in New York, NY from June 8-10, 2022.
- 05/31/2022
|
AC Immune to Present at the B. Riley Annual Neuro & Ophthalmology Virtual Investor Conference
- LAUSANNE, Switzerland, April 27, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will participate in a Fireside chat and one-on-one investor meetings during the B.Riley Annual Neuro & Ophthalmology Virtual Investor Conference, taking place virtually on April 27-28, 2022.
- 04/27/2022
|
AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs
- Five presentations at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD TM )
- 02/28/2022
|
AC Immune-Janssen Partnered Alzheimer's Vaccine Shows Tau-Specific Antibodies In Early-Stage Trial
- AC Immune SA (NASDAQ: ACIU) and partner Janssen, a unit of Johnson & Johnson (NYSE: JNJ), have found that an early-stage Alzheimer's vaccine spurs induction of antibodies that attack a type of tau, a protein in the brain that contributes to the disease. The interim data for ACI-35.030 come from the high-dose group in Phase 1b/2a trial of patients with early Alzheimer's.
- 02/15/2022
|
AC Immune to Present at the SVB Leerink 11th Annual Global Healthcare Conference
- LAUSANNE, Switzerland, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will participate in a fireside chat and one-on-one investor meetings during the SVB Leerink 11th Annual Global Healthcare Conference, taking place virtually February 14-18, 2022.
- 02/02/2022
|
AC Immune (ACIU) Reports Q3 Loss, Misses Revenue Estimates
- AC Immune (ACIU) delivered earnings and revenue surprises of 17.24% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/08/2021
|
AC Immune (ACIU) Stock: Why The Price Increased Today
- The stock price of AC Immune SA (NASDAQ: ACIU) increased over 9% pre-market today. This is why it happened.
- 11/08/2021
|
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline
- AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 11/05/2021
|
AC Immune to Present at the Jefferies London Healthcare Conference
- LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will participate in a fireside chat and one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021.
- 10/25/2021
|
Alzheimer's Drug for Roche Partner AC Immune Shows Promise
- The ardor for shares of AC Immune SA ( ACIU , Financial) has cooled considerably since the company's Aug. 31 announcement of somewhat promising study results for its Alzheimer's drug. The Swiss biotech's stock shot up to a 52-week high of $12.61, but has since been halved as investors questioned how meaningful the trial results were.
- 09/16/2021
|
AC Immune CEO Andrea Pfeifer Receives First SEF.WomenAward for CEO of the Year
- LAUSANNE, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced its Co-Founder and CEO Andrea Pfeifer has been awarded by the Swiss Economic Forum (SEF) with the SEF.WomenAward, in the category CEO of the Year, during a ceremony at the SEF meeting in Interlaken on September 2, 2021.
- 09/03/2021
|
AC Immune to Participate in Upcoming Virtual Investor Conferences in September
- LAUSANNE, Switzerland, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in the following upcoming virtual investor conferences:
- 09/02/2021
|
AC Immune's (ACIU) Stock Up Despite Mixed Data From AD Study
- AC Immune's (ACIU) candidate for mild-to-moderate AD meets one of the two co-primary endpoints. Resultantly, the stock price rises 16%
- 09/01/2021
|
What Leerink, Wainwright Have To Say For This Alzheimer's Focused Firm
- Earlier today, AC Immune SA (NASDAQ:ACIU) announced semorinemab met one of its co-primary endpoints in a mid-stage Alzheimer's disease trial. SVB Leerink notes that semorinemab data is "good news.
- 08/31/2021
|
ACIU Stock: The Big Alzheimer's News That Has AC Immune Skyrocketing Today
- AC Immune (ACIU) stock is rising higher on Tuesday after revealing positive results from a recent Alzheimer's disease study. The post ACIU Stock: The Big Alzheimer's News That Has AC Immune Skyrocketing Today appeared first on InvestorPlace.
- 08/31/2021
|
Here's Why AC Immune Stock Is Surging Today
- MIxed results for the company's Alzheimer's disease candidate are good enough for the market today.
- 08/31/2021
|
Biopharmaceutical Stock Blasts Higher on Alzheimer's Treatment Update
- The shares of Switzerland-based biopharmaceutical company AC Immune SA (NASDAQ:ACIU) are soaring this morning, up 72.4% to trade at $12.04 at last check.
- 08/31/2021
|
ACIU Stock: Over 65% Increase Pre-Market Explanation
- The stock price of AC Immune SA (NASDAQ: ACIU) increased by over 65% pre-market. This is why it happened.
- 08/31/2021
|
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer's Disease
- Top-line data from Lauriet Phase 2 trial of semorinemab in mild-to-moderate AD shows a statistically significant reduction on one of two co-primary endpoints, ADAS-Cog11
- 08/31/2021
|
AC Immune (ACIU) Reports Q2 Loss, Lags Revenue Estimates
- AC Immune (ACIU) delivered earnings and revenue surprises of -31.82% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2021
|
AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- Announced strategic acquisition of industry-leading Parkinson's disease vaccine and equity investment led by key investors in Covid-19 vaccine innovator BioNTech SE
- 08/04/2021
|
AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkinson's Disease at AAIC 2021
- ACI-24 generated an encouraging immune response that correlated with a signal of target engagement in patients with Down syndrome (DS)
- 07/29/2021
|
AC Immune Secures Funding From BioNTech Investors, Buys Parkinson's Vaccine Candidate
- AC Immune SA (NASDAQ: ACIU) has gained a multi-million investment from the principal backers of BioNTech SE (NASDAQ: BNTX) while acquiring a possible Parkinson's disease vaccine. It announced a $25 million private share placement with a group of investors led by Athos Service GmbH.
- 07/27/2021
|
AC Immune acquires AFFiRiS' Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases
- VIENNA, Austria, July 27, 2021 (GLOBE NEWSWIRE) -- AFFiRiS AG, a clinical-stage biotechnology company that has been engaged in the development of novel disease-modifying Specific Active Immunotherapies (SAITs), today announced that AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, is acquiring AFFiRiS' anti-alpha-synuclein programs targeting neurodegenerative diseases caused by misfolded forms of human self-proteins. All acquired programs are based on AFFiRiS´ AFFITOME® technology.
- 07/27/2021
|
AC Immune Announces Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH
- All-stock transaction maintains AC Immune's strong cash position
- 07/27/2021
|
AC Immune Holds its Annual General Meeting of Shareholders
- LAUSANNE, Switzerland, June 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that AC Immune held its Annual General Meeting per Swiss law. Shareholders cast their votes through the independent proxy appointed by the shareholders.
- 06/25/2021
|
ACIU Stock Price: Over 20% Increase Pre-Market Explanation
- The stock price of AC Immune SA (NASDAQ: ACIU) increased by over 20% pre-market. This is why it happened.
- 06/02/2021
|
AC Immune Stock Jumps After Alzheimer's Disease Vaccine Candidate Confirms Favorable Safety, Tolerability Profile
- AC Immune SA (NASDAQ: ACIU) has completed an 18-month interim assessment of safety and tolerability in the Phase 2 study evaluating ACI-24, its vaccine candidate for mild Alzheimer's disease (AD). No safety concerns or evidence for CNS inflammation or ARIA (amyloid-related imaging abnormalities) were observed, confirming earlier interim results.
- 06/02/2021
|
AC Immune to Highlight First-in-Class Alzheimer's Disease Vaccine Programs at Upcoming Investor Conferences
- LAUSANNE, Switzerland, May 20, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it will participate in the UBS Global Healthcare Virtual Conference and the Jefferies Virtual Healthcare Conference, taking place May 24-26, 2021 and June 1-4, 2021, respectively.
- 05/20/2021
|
AC Immune Provides Update On Alzheimer's Disease Vaccine Candidate
- AC Immune SA (NASDAQ: ACIU) and its partner Janssen Pharmaceuticals Inc have expanded the ongoing Phase 1b/2a trial evaluating anti-phosphorylated-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer's disease (AD). The trial expansion specifically includes vaccination of additional AD patients at the second-highest dose.
- 05/17/2021
|
AC Immune (ACIU) Reports Q1 Loss, Misses Revenue Estimates
- AC Immune (ACIU) delivered earnings and revenue surprises of -19.05% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 04/28/2021
|
AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate Update
- LAUSANNE, Switzerland, April 28, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the quarter ended March 31, 2021. The Company also provided an overview of its recent clinical and corporate highlights and anticipated milestones for 2021.
- 04/28/2021
|
AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of Directors
- Dr. Colowick has more than 20 years of experience in large and emerging biotech companies
- 03/31/2021
|
AC Immune Hosts Investor Webinar Highlighting the Power of its Morphomer™ Platform to Enable Precision Medicine for Neurodegenerative Disease
- Clinically validated platform accelerates the discovery and development of first-in-class small molecule therapeutics in parallel with companion diagnostics Clinically validated platform accelerates the discovery and development of first-in-class small molecule therapeutics in parallel with companion diagnostics
- 03/31/2021
|
AC Immune to Host Webinar Highlighting its Innovative Morphomer™ Technology Platform and Pipeline
- Therapeutic and diagnostic Morphomers™ enable AC Immune's unique precision medicine approach for neurodegenerative diseases
- 03/26/2021
|
AC Immune: Old Theory, New Company
- ACIU is developing drugs for Alzheimer's disease.
- 03/26/2021
|
Recap: AC Immune Q4 Earnings
- Shares of AC Immune (NASDAQ:ACIU) moved higher by 3.4% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were flat 0.00% over the past year to ($0.28), which missed the estimate of ($0.27).
- 03/23/2021
|
Why Can-Fite, Moderna, AC Immune Shares Are Rallying
- Moderna Inc. (NASDAQ: MRNA), AC Immune SA (NASDAQ: ACIU) and Can-Fite BioPharma Ltd. (NYSE: CANF) were among the early biotech movers Tuesday.
- 03/16/2021
|
AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases
- Four presentations at AD/PD™ 2021 feature latest findings from wholly owned therapeutic and diagnostic programs targeting pathological forms of alpha-synuclein and TDP-43
- 03/09/2021
|
Why AC Immune Stock Surged Today
- Researchers are excited about the potential of the biotech's investigational Alzheimer's vaccine.
- 02/11/2021
|
ACIU Stock: Why AC Immune Shares Are Rocketing Higher Today
- Swiss biopharma AC Immune has released positive updates this week on both its Alzheimer's and Parkinson's disease treatments. Investors are piling in to ACIU stock.
- 02/11/2021
|
ACIU Stock Price Increases Over 130% Pre-Market: Why It Happened
- The stock price of AC Immune SA (NASDAQ: ACIU) is trading at over 130% pre-market. This is why it happened.
- 02/11/2021
|
AC Immune's Alzheimer's Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study
- Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer's disease
- 02/11/2021
|
AC Immune Initiates Clinical Study of First-in-class Diagnostic for Parkinson's Disease
- LAUSANNE, Switzerland, Feb. 08, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that the first patient has been scanned in a first-in-human study of its novel diagnostic agent for Parkinson's disease (PD). ACI-12589 is a next-generation positron emission tomography (PET) imaging tracer that has shown significant potential to reliably detect and map deposits of pathological alpha-synuclein protein in the brain, which is the major hallmark of PD. AC Immune expects to report the results of the study in Q3 2021. The clinical study is supported by the Michael J. Fox Foundation for Parkinson's Research (MJFF), building on The Foundation's significant funding of AC Immune's program since 2015.
- 02/08/2021
|
AC Immune Reports Progress for Therapeutic Programs Targeting the NLRP3 Inflammasome Pathway
- Highly potent in vivo anti-inflammatory activity demonstrated for novel small molecule NLRP3 inhibitors
- 01/29/2021
|
AC Immune Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay
- Grant provides USD 600,000 in funding to support a world-class collaboration between AC Immune and Massachusetts General Hospital
- 12/15/2020
|
Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune's Board of Directors
- Prof. June is a world authority on immune tolerance and adoptive immunotherapy
- 11/20/2020
|
Neurologist and Psychiatrist Prof. Johannes Rolf Streffer, MD Joins AC Immune SA as Chief Medical Officer
- Prof. Streffer is a n established authority on n euroscience and b iomarker modalities
- 11/18/2020
|
AC Immune: Q3 Earnings Insights
- Shares of AC Immune (NASDAQ:ACIU) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share were down 204.00% over the past year to ($0.26), which beat the estimate of ($0.28).
- 11/13/2020
|
AC Immune Reports Q3 2020 Financial Results and Provides Business Update
- LAUSANNE, Switzerland, Nov. 13, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for Q3 2020 and provided a business update. The Company ended the third quarter with CHF 246.6 million in cash, which ensures operations are fully financed through Q1 2024 allowing the Company to advance our clinical and preclinical projects to key value inflection points while investing further in our diverse pipeline.
- 11/13/2020
|
AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune's Anti-TDP-43 Antibodies into Clinical Development
- Strategic partnership reflects AC Immune's growing expertise in monoclonal antibody development Strategic partnership reflects AC Immune's growing expertise in monoclonal antibody development
- 11/09/2020
|
AC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma
- AC Immune suffers setback on Alzheimer's front. Galera Therapeutics provides positive update of GC4419 in pancreatic cancer.
- 10/30/2020
|
Aerie (AERI) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
- Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.
- 08/07/2020
|
All You Need to Know About AC Immune (ACIU) Rating Upgrade to Strong Buy
- AC Immune (ACIU) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 08/06/2020
|
AC Immune (ACIU) Reports Q2 Loss, Tops Revenue Estimates
- AC Immune (ACIU) delivered earnings and revenue surprises of 25.00% and 215.71%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/05/2020
|
AC Immune Reports Q2 2020 Financial Results and Provides Business Update
- * Substantial progress achieved across three anti-Tau clinical development programs; all clinical and preclinical programs remain on track to generate value in the second half of 2020 * Top line Phase 2 data expected in the second half of 2020 for anti-Tau antibody semorinemab * CHF 262.5 million in cash ensures operations are fully financed through Q1 2024 * Michael J. Fox Foundation (MJFF) award of USD 3.2 million (CHF 3.1 million) to support our alpha-synuclein positron emission tomography-(PET) tracer program for Parkinson’s disease (PD) diagnosticsLAUSANNE, Switzerland, Aug. 05, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for the Q2 2020 and provided a business update. The Company ended the second quarter with CHF 262.5 million in cash, which ensures operations are fully financed through Q1 2024 with the potential to achieve multiple clinical milestones and create substantial value inflection.Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “AC Immune has delivered outstanding pipeline progress in Q2 2020, having achieved meaningful milestones across all three of our anti-Tau therapeutic programs including initiation of the second highest dosing group in our Phase 1b/2a clinical trial evaluating ACI-35.030, our vaccine candidate for the treatment of Alzheimer’s disease (AD). In addition, we are proud to report that all of our programs continue to advance on schedule and additional substantial clinical data readouts continue to be anticipated in the second half of 2020, including top line Phase 2 data for our anti-Tau antibody semorinemab, from our partner Genentech, a member of the Roche group. “This strong clinical execution is mirrored by the productivity of our SupraAntigenTM and MorphomerTM discovery platforms, which continue to enable us to advance additional novel candidates against high value therapeutic targets, such as TDP-43, alpha-synuclein, and neuroinflammation. To achieve multiple clinical and preclinical therapeutic and diagnostic milestones in the first half of this year as planned – during the global pandemic – is truly exceptional and it shines a light on the diligence and dedication of our team and collaborators as well as the cutting-edge science fueling our pipeline. “We continue to maintain our strong cash position as we advance our development pipeline and we are well positioned to capture additional value from the new projects out of the SupraAntigenTM and MorphomerTM platforms, as we are already doing with our partnered programs. Complementing our achievements this quarter, results published in JAMA Neurology provide important clinical validation of the unique diagnostic potential of our Tau-PET tracer PI-2620, which is being developed in collaboration with Life Molecular Imaging, for patients with progressive supranuclear palsy (PSP). We are especially proud that our alpha-synuclein-PET tracer program was awarded USD 3.2 million by the MJFF Ken Griffin Alpha-synuclein Imaging Competition. This tracer program is recognized as the most advanced in the field and could deliver the world’s first imaging agent capable of accurately detecting and monitoring progression of PD.” Q2 2020 Research & Development Highlights: * Initiation of investigational new drug (IND)-enabling studies for the Company’s first-in-class therapeutic antibody targeting TDP-43. The anti-TDP-43 antibody is the first therapeutic candidate shown to mitigate TDP-43 neuropathology in vivo and the Company plans to develop the antibody for the treatment of NeuroOrphan indications * AC Immune is one of three winners sharing USD 10 million through The Michael J. Fox Foundation Ken Griffin Alpha-synuclein Imaging Competition. The funding will support the nonclinical and clinical investigation of the Company’s alpha-synuclein-PET tracers, which are the most advanced in the field and could deliver the world’s first imaging agent capable of accurately detecting and monitoring progression of PD * New data presented at the Alzheimer’s Association International Conference (AAIC) on the next generation alpha-synuclein-PET tracer shows enhanced contrast and alpha-synuclein target specificity, putting AC Immune’s tracer in a strong position to become a first-in-class precision diagnostic tool for PD. AC Immune anticipates advancing its lead compound toward clinical stage development in Q4 2020 * Announced the initiation of the second highest dosing group in the Company’s Phase 1b/2a clinical trial evaluating ACI-35.030. The vaccine candidate, which is being developed in collaboration with Janssen Pharmaceuticals, Inc., is the first clinical candidate designed to generate a specific antibody response against pathological phospho-Tau (pTau) proteins in the brain. The decision to advance to the higher dosing group follows encouraging interim safety, tolerability and immunogenicity results from the initial dosing group * Results of an observational clinical study published in JAMA Neurology showed that PI-2620, an investigational Tau-PET tracer, can facilitate an earlier and more reliable diagnosis of PSP * Presented the cutting-edge science behind AC Immune’s therapeutic and diagnostic programs in TDP-43 and alpha-synuclein, which are amongst the most comprehensive in the field, to investors at the UBS Virtual Healthcare Conference. Both targets are considered to be major pathologies in neurodegenerative diseases and are increasingly thought to be important co-pathologies in AD and PDUpdate on Covid-19 The Swiss Government’s management of Covid-19 has allowed businesses to be able to return to near normal working practices, with all AC Immune staff now back on site in Lausanne. AC Immune remains in continuous contact with its partners and other important stakeholders, including the Swiss government, trial investigators and contractors, and at this stage the Company is not modifying guidance with respect to the multiple clinical and preclinical data readouts anticipated this year. AC Immune will continue to keep the market apprised of any new developments or information that may impact clinical timelines.Analysis of Financial Statements for the Three and Six Months Ended June 30, 2020 * Revenues: Revenues for the three and six months ended June 30, 2020 totaled CHF 1.3 million and CHF 13.7 million, respectively. This represents a decrease of CHF 0.2 million and CHF 62.9 million over the comparable periods in 2019. The decrease for the three months ended June 30, 2020 relates to a decrease of CHF 0.6 million in our collaboration with Janssen and other partners offset by a CHF 0.4 million increase with Eli Lilly and Company. The decrease for the six months ended June 30, 2020 predominantly relates to CHF 74.3 million recognized in the prior period associated with our license agreement with Lilly offset by a recognition of a CHF 10 million milestone payment and CHF 2.9 million for research and development activities performed in the current period * R&D Expenditures: For the three and six months ended June 30, 2020, R&D expenses increased by CHF 0.1 million (+1%) and CHF 3.7 million (+15%) to CHF 12.9 million and CHF 28 million, respectively. For R&D expenses directly allocated to R&D programs, the Company increased investments in its non-AD programs predominantly led by increases in ACI-24 in Down syndrome related to scaling up activities for a Phase 2 clinical study. For AD, the Company’s expenditures for ACI-24 in AD decreased due to the advanced status of the second generation vaccine technology Additionally, personnel costs in R&D increased by CHF 0.7 million and CHF 1.3 million through an increase in total 15 FTEs for the three and six months ended June 30, 2020, respectively. The remaining increases of CHF 0.3 million and CHF 0.9 million relate to an increase in regulatory and quality assurance and other unallocated research and development costs * G&A Expenses: For the three and six months ended June 30, 2020, G&A increased CHF 0.6 million (+16%) and CHF 1.8 million (+26%) to CHF 4.2 million and CHF 8.7 million, respectively. Increases were driven by an addition of seven FTEs as well as an increase in administrative and depreciation expenses * IFRS (Loss)/Income for the period: The Company incurred net loss after taxes of CHF 15.7 million and CHF 23.4 million for the three and six months ended June 30, 2020, respectively, compared with a net loss of CHF 16.9 million and net income of CHF 46.7 million for the comparable periods in 2019, predominantly as a result of the CHF 74.3 million of revenues recognized from our Lilly collaboration in 2019 * Cash Position: The Company had a total cash balance of CHF 262.5 million, comprised of CHF 177.5 million in cash and cash equivalents and CHF 85 million in short-term financial assets. This compares to a total cash balance of CHF 288.6 million as of December 31, 2019. This decrease of CHF 26.1 million is principally due to the factors noted above in the income statement which resulted in a CHF 23.4 million net loss for the period and changes in our working capital. Further details are available in our Statements of Cash Flows on the accompanying Form 6-KAbout AC Immune SA AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigenTM and MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins.
- 08/05/2020
|
AC Immune Initiates IND-Enabling Studies for First-in-Class Antibody Targeting TDP-43 to Treat Neurodegeneration
- First-in-class TDP-43 antibody developed using SurpraAntigen™ platform The only TDP-43 antibody with reported in vivo activity LAUSANNE, Switzerland, Aug. 03, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, with a broad pipeline focused on neurodegenerative diseases, today announced the initiation of investigational new drug (IND)-enabling studies for the Company’s first-in-class therapeutic antibody targeting TDP-43 (TAR DNA-binding protein 43). The anti-TDP-43 antibody is the first therapeutic candidate shown to mitigate TDP-43 neuropathology in vivo and the Company plans to develop the antibody for the treatment of NeuroOrphan indications.Advancing the anti-TDP-43 antibody towards clinical development is the latest in a series of important milestones already achieved this year in the Company’s cutting-edge therapeutic and diagnostic programs targeting TDP-43 – which are amongst the most comprehensive in the field. TDP-43 pathology is strongly associated with cognitive decline and episodic memory loss in neurodegenerative diseases. Effectively slowing or stopping the spread of TDP-43 pathology throughout the brain could provide the first TDP-43 targeted therapeutic approach for treating conditions such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP), where almost half of all FTLD cases exhibit TDP-43 pathology with significant market potential for AC Immune’s TDP-43 antibody. Other indications include limbic-predominant age-related TDP-43 encephalopathy (LATE), and sub-populations of argyrophilic grain disease and Lewy Body Dementia. Additionally, pathological aggregation of TDP-43 has emerged as an important co-pathology in Alzheimer’s disease linked to disease severity and occurring in ~50% of patients. Recognition that neurodegenerative diseases are driven by a complex interplay of pathologies highlights that successful treatments and cures will likely require combination therapy powered by precision medicine. This diversified approach is pioneered by AC Immune through parallel development of highly selective therapeutics and diagnostics for established targets like Tau and Abeta alongside newer targets such as TDP-43.Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “This milestone reinforces AC Immune’s position as a leader in developing novel therapies against neurodegenerative diseases, with our anti-TDP-43 antibody on track to become the first in the world to reach clinical development. Aggregation of pathological forms of TDP-43 is an increasingly validated therapeutic target and a well-established hallmark of neurodegeneration. Initiation of IND-enabling studies for our first-in-class lead anti-TDP-43 antibody is a major step toward addressing pressing unmet need in NeuroOrphan indications.“The Company’s success is driven in part by our proprietary SupraAntigen™ platform, which has already produced therapeutic monoclonal antibody candidates targeting Abeta and Tau that were successfully out-licensed to leading pharmaceutical companies and are currently advancing in multiple Phase 2 clinical studies. Advancement of the anti-TDP-43 antibody further validates the continuing productivity of this platform, which, together with our Morphomer™ platform for small molecule development, are responsible for discovery and development of our maturing pipeline of first-in-class or best-in-class therapeutic and diagnostic candidates.”TDP-43 is an RNA/DNA-binding protein that functions primarily in the nucleus as a regulator of gene transcription and RNA metabolism. TDP-43 pathology has been shown to start from a focal point in the brain and spread to other brain regions with disease progression. Antibody-mediated clearance of pathological TDP-43 therefore represents an attractive strategy for therapeutic intervention – potentially slowing the spread by blocking the ability of pathological TDP-43 to seed aggregation in neighboring healthy cells. The anti-TDP-43 antibody binds all forms of TDP-43 with high affinity and is the only antibody with reported in vivo activity. Proof-of-concept data presented at the 2020 AAT-AD/PD™ Conference demonstrated anti-TDP-43 antibody’s ability to mitigate TDP-43 neuropathology in a mouse model of TDP-43 proteinopathies.About AC Immune SA AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigen™ and Morphomer™, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche group, Eli Lilly and Company, and Janssen Pharmaceuticals.For further information, please contact:Head of Investor Relations Joshua Drumm, Ph.D. AC Immune Phone: +1 917 809 0814 Email: joshua.drumm@acimmune.com US Media Katie Gallagher LaVoieHealthScience Phone: +1 617 792 3937 Email: kgallagher@lavoiehealthscience.com Global Head of Communications Judith Moore AC Immune Phone: +41 79 826 63 82 Email: judith.moore@acimmune.com European Investors & Media Chris Maggos LifeSci Advisors Phone: +41 79 367 6254 Email: chris@lifesciadvisors.com Forward looking statementsThis press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
- 08/03/2020
|
AC Immune Wins Prestigious Award to Develop a “Game-Changing” Parkinson’s Diagnostic Tool
- AC Immune is one of three winners sharing USD 10 million through The Michael J. Fox Foundation Ken Griffin Alpha-synuclein Imaging Competition The award follows compelling preclinical results presented at AAIC on the Company’s alpha-synuclein positron emission tomography -(PET) tracer program Further validates the ability of AC Immune’s proprietary platforms to accelerate delivery of a new class of promising diagnostics in neurodegenerative diseases LAUSANNE, Switzerland, July 30, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it is one of the winners of the Ken Griffin Alpha-synuclein Imaging Competition from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), and is eligible to receive together with its partner USD 3.2 million (CHF 3.1 million).The funding will support the nonclinical and clinical investigation of AC Immune’s proprietary alpha-synuclein-PET tracers, which are the most advanced in the field and could deliver the world’s first imaging agent capable of accurately detecting and monitoring progression of Parkinson’s disease (PD). The clinical arm of the AC Immune project will be conducted in partnership with Prof. Oskar Hansson’s team of world-class researchers at Lund University and Skåne University Hospital in Sweden, which is a recognized Center of Excellence in the field of diagnostics for neurodegenerative diseases. Skåne University Hospital is eligible to receive USD 0.7 million over two years to support this arm of the project.Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “AC Immune is very proud to have attracted repeated support from MJFF over the last five years to advance development of alpha-synuclein-PET tracers. This award follows compelling preclinical results presented this week at the Alzheimer’s Association International Conference (AAIC) on our next generation PET tracer which demonstrates enhanced contrast and alpha-synuclein target specificity, putting our tracer in a strong position to become a first-in-class precision diagnostic tool for Parkinson’s disease (PD). This is a particularly important area of research, and this award really demonstrates the power of our innovative Morphomer™ discovery platform to accelerate the design, development and synthesis of conformation-specific small molecules. An effective alpha-synuclein PET tracer would enable and accelerate the development of new PD therapies as a powerful tool for measuring the effect of novel drugs on alpha-synuclein pathology in the brain.”Jamie Eberling, Ph.D, Vice President of Research at MJFF, said: “The Foundation is committed to the development of an imaging tracer for Parkinson’s. AC Immune has already advanced alpha-synuclein tracers to human clinical testing, and we look forward to its progress as it continues clinical testing and develops new tracers.”The MJFF award for AC Immune’s alpha-synuclein-PET program follows the announcement at this year’s AAT-AD/PD™ conference that the Company’s SupraAntigen™-derived anti-alpha-synuclein therapeutic antibody candidate has advanced into preclinical development to treat PD and other synucleinopathies. The combined potential of AC Immune’s therapeutic and diagnostic programs is based on the Company’s capabilities in precision medicine and may improve the diagnosis and treatment of alpha-synuclein pathologies, which are also of increasing interest in Alzheimer’s disease (AD) and NeuroOrphan indications.Prof. Oskar Hansson, of Lund University and Skåne University Hospital said: “It would be a huge step forward if we succeed in the development of an accurate and reliable PET method for detection of alpha-synuclein pathology. Such a diagnostic method would be vital for increasing our understanding of the diseases, and more importantly it would facilitate the development of new disease modifying therapies that might halt, or even stop, the progression of PD.”Prof. Pfeifer continued: “Our second generation alpha-synuclein-PET tracer started a first-in-human study last year and plans are in place to start another study to evaluate this tracer in genetic populations and, in parallel, advance a third generation candidate to clinical stage. With this latest award from MJFF, we look forward to advancing this important diagnostic program in collaboration with Prof. Hansson at Lund University and Skåne University Hospital.”About AC Immune’s alpha-synuclein programs Alpha-synuclein misfolding, aggregation and seeding are the molecular basis for the formation of Lewy bodies, a hallmark of PD, multiple system atrophy, and Lewy Body Dementia. Antibody-mediated clearance of pathological alpha-synuclein, including Lewy bodies, represents an attractive strategy for therapeutic intervention. Availability of non-invasive diagnostic tools like PET imaging agents would allow accurate diagnosis and monitoring of disease progression and would potentially enable longitudinal drug efficacy measurements in patients.AC Immune’s PET tracers are derived from the Company’s innovative Morphomer™ discovery platform, which accelerates the design, development and synthesis of conformation-specific small molecules to power successful diagnostic and therapeutic approaches. The Morphomer™ platform has produced multiple small molecules with clinical proof-of-concept that bind selectively to pathological forms of human proteins such as alpha-synuclein and Tau. It is complemented by AC Immune’s SupraAntigen™ platform, which has generated clinically validated monoclonal antibodies and vaccines directed against pathological forms of Tau and Abeta. Together, these platforms have attracted partnerships with leading, global pharmaceutical companies, including Genentech, a member of the Roche group, Janssen Pharmaceuticals and Eli Lilly and Company, and have established AC Immune as an industry leader in the development of novel diagnostic and therapeutic agents for neurodegenerative diseases.About the Michael J. Fox Foundation Ken Griffin Alpha-synuclein Imaging Competition MJFF is the world's largest nonprofit funder of Parkinson's research with pioneering collaborations across industry, academia and government. This new award from the Ken Griffin Alpha-synuclein Imaging Competition is largely funded through a USD 7.5 million leadership gift from Ken Griffin, Founder and CEO of the Chicago-based global investment firm, Citadel, to incentivize research teams to race to develop a game-changing Parkinson’s diagnostic tool. The USD 10 million Ken Griffin Alpha-synuclein Imaging Competition will be shared between three winning proposals in two rounds of funding with USD 8.5 million initially shared over two years. The final USD 1.5 million will then be awarded to the team that has progressed furthest to develop its program.About AC Immune SA AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigen™ and Morphomer™, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche group, Eli Lilly and Company and Janssen Pharmaceuticals.For further information, please contact:Head of Investor Relations Joshua Drumm, Ph.D. AC Immune Phone: +1 917 809 0814 Email: joshua.drumm@acimmune.com US Media Katie Gallagher LaVoieHealthScience Phone: +1 617 792 3937 Email: kgallagher@lavoiehealthscience.com Global Head of Communications Judith Moore AC Immune Phone: +41 79 826 63 82 Email: judith.moore@acimmune.com European Investors & Media Chris Maggos LifeSci Advisors Phone: +41 79 367 6254 Email: chris@lifesciadvisors.com Forward looking statements This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
- 07/30/2020
|
AC Immune Demonstrates Enhanced Performance of First-in-class Parkinson’s Diagnostic Agent
- Next-generation PET tracer detects pathological alpha-synuclein with improved signal-to-noise ratio Oral presentation at AAIC further demonstrates the strength of AC Immune’s Morphomer™ platform for generating highly selective small molecule diagnostics LAUSANNE, Switzerland, July 28, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, with a broad pipeline focused on neurodegenerative diseases, today reported new data for its next generation alpha-synuclein positron emission tomography-(PET) tracer during an oral presentation at the Alzheimer’s Association International Conference (AAIC) and anticipates advancing its lead compound toward clinical stage development in Q4 2020.The compelling preclinical results demonstrate enhanced contrast and alpha-synuclein target specificity, putting AC Immune’s PET tracer in a strong position to become a first-in-class precision diagnostic tool for Parkinson’s disease (PD). No effective diagnostic agents exist today for PD and other alpha-synucleinopathies, such as multiple system atrophy (MSA), and Lewy Body Dementia (LBD), representing substantial unmet clinical need.Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “I am highly encouraged by these results, as they demonstrate AC Immune’s industry-leading expertise in the development of alpha-synuclein-targeting agents. There is increasing recognition of the importance of targeting the right disease pathology at the right time in neurodegenerative diseases, and AC Immune continues to lead the way towards facilitating such an approach through the parallel development of therapeutic and diagnostic agents for important targets such as alpha-synuclein, as well as more well established targets like Tau and Abeta. The data presented at AAIC are a prime example of the power of our Morphomer™ platform to facilitate the rapid optimization of our PET tracers.”Alpha-synuclein misfolding, aggregation and seeding are the molecular basis for the formation of Lewy bodies, a hallmark of PD, MSA, and LBD. The availability of non-invasive diagnostic tools that can distinguish alpha-synucleinopathies from other proteinopathies or normal physiological situations would enable – for the first time – accurate clinical diagnosis, monitoring of disease progression and benefits of drug interventions. ACI-12589 demonstrates significantly increased target occupancy compared to previous-generation candidates as well as a significantly improved signal specificity.AC Immune’s PET tracers are derived from the Company’s innovative Morphomer™ discovery platform, which accelerates the design, development and synthesis of conformation-specific small molecules to power successful diagnostic and therapeutic approaches. The Morphomer™ platform has produced multiple small molecules with clinical proof-of-concept that bind selectively to pathological forms of human proteins such as alpha-synuclein and Tau.Based on proof-of-concept data presented at this year’s AAT-AD/PD™ conference, AC Immune announced that it advanced its SupraAntigen™-derived anti-alpha-synuclein therapeutic antibody candidate from discovery into preclinical development. The combined potential of AC Immune’s therapeutic and diagnostic programs is based on the Company’s capabilities in precision medicine and may improve the diagnosis and treatment of alpha-synuclein pathologies, which are of increasing interest in Alzheimer’s disease (AD) and NeuroOrphan indications.Dr. Capotosti’s presentation was titled Developing a novel alpha-synuclein positron emission tomography (PET) tracer for the diagnosis of a-synucleinopathies. Key highlights from the presentation include: * ACI-3847, a first-generation alpha-synuclein-PET tracer, showed good brain uptake and very low non-specific retention in a first-in-human study in idiopathic PD patients and healthy volunteers * The data on ACI-3847 suggested to test the PET tracer in alpha-synuclein-pathologies with higher levels of alpha-synuclein accumulation * AC Immune’s Morphomer™ platform also led to the discovery of ACI-12589 with excellent target occupancy and signal specificity ex vivo and an expected optimal signal-to-noise ratio in patients * Data presented will show ACI-12589 as a potential first- and best-in-class imaging agent for the diagnosis of PDAbout AC Immune SA AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigen™ and Morphomer™, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company and Janssen Pharmaceuticals.For further information, please contact:Head of Investor Relations Joshua Drumm, Ph.D. AC Immune Phone: +1 917 809 0814 Email: joshua.drumm@acimmune.com US Media Katie Gallagher LaVoieHealthScience Phone: +1 617 792 3937 Email: kgallagher@lavoiehealthscience.com Global Head of Communications Judith Moore AC Immune Phone: +41 79 826 63 82 Email: judith.moore@acimmune.com European Investors & Media Chris Maggos LifeSci Advisors Phone: +41 79 367 6254 Email: chris@lifesciadvisors.com Forward looking statements This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
- 07/28/2020
|
AC Immune to Present Advances in Two of the Company’s World Leading Programs at the Upcoming Alzheimer’s Association International Conference
- Presentations to highlight the Company’s broad expertise addressing both novel and well-established targets in neurodegenerative diseasesLAUSANNE, Switzerland, July 23, 2020 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, with a broad pipeline focused on neurodegenerative diseases, today announced two oral presentations will be delivered at this year’s Alzheimer’s Association International Conference (AAIC) which takes place virtually July 27 – 31, 2020.Key data will be presented on the Company’s alpha-synuclein-positron emission tomography (PET) tracer program along with a second oral presentation by the Coordinating Principal Investigator of the Phase 1b trial of the anti-Abeta vaccine ACI-24 in Down syndrome, Dr. Michael Rafii – who is a world authority on Down syndrome-related Alzheimer’s disease. Both research programs are the most advanced in their field.Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “This year’s AAIC presentations reflect the ongoing strength and depth of our industry leading pipeline. There is increasing recognition that the complexity of neurodegenerative disease pathology will only be solved utilizing the type of diversified approach pioneered by AC Immune. This is why our pipeline spans both cutting-edge therapeutic and diagnostic programs on well-established targets like Abeta, as well as novel targets and mechanisms.“Compelling results1 just published from the first large, multi-national study to track clinical and biomarker changes of Down syndrome-related Alzheimer’s disease further validate the approach of testing our anti-Abeta vaccine ACI-24 in individuals with Down syndrome as a key population for trials to target Alzheimer’s disease in genetic, more homogeneous populations.“The presentations further highlight the enduring power of our clinically validated proprietary Morphomer™ and SupraAntigen™ platforms to accelerate the discovery, design and development of novel medicines and diagnostics to target misfolded proteins.”Scientific updates at the AAIC 2020 Virtual Event, July 27–31, 2020Alpha-synuclein PET tracer Title: Developing a novel alpha-synuclein-positron emission tomography (PET) tracer for the diagnosis of a-synucleinopathies Date: Tuesday, July 28, 2020 | 12:00am – 11:59pm Session: Neuroimaging: Other Neurodegenerative Disorders Presenter: Oral presentation by Dr. Francesca Capotosti ACI-24 anti-Abeta vaccine Title: ACI-24 Vaccine in Adults with Down Syndrome (3 Star Trial) Date: Wednesday, July 29, 2020 | 12:00 am – 11:59pm Session: Human: Putative Therapeutic Results for Alzheimer's and Related Dementias Presenter: Oral presentation by Dr. Michael Rafii, Alzheimer’s Therapeutic Research Institute, Keck School of Medicine of University of Southern California References 1. Fortea et al, Lancet 2020; 395: 1988–97About AC Immune SA AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases. The Company utilizes two proprietary platforms, SupraAntigenTM and MorphomerTM, to design, discover and develop small molecule and biological therapeutics as well as diagnostic products intended to diagnose, prevent and modify neurodegenerative diseases caused by misfolding proteins. The Company's pipeline features nine therapeutic and three diagnostic product candidates, with six currently in clinical trials. It has collaborations with major pharmaceutical companies including Genentech, a member of the Roche group, Eli Lilly and Company and Janssen Pharmaceuticals.For further information, please contact:Head of Investor Relations Joshua Drumm, Ph.D. AC Immune Phone: +1 917 809 0814 Email: joshua.drumm@acimmune.com US Media Katie Gallagher LaVoieHealthScience Phone: +1 617 792 3937 Email: kgallagher@lavoiehealthscience.com Global Head of Communications Judith Moore AC Immune Phone: +41 79 826 63 82 Email: judith.moore@acimmune.com European Investors & Media Chris Maggos LifeSci Advisors Phone: +41 79 367 6254 Email: chris@lifesciadvisors.com Forward looking statements This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.
- 07/23/2020
|
AC Immune Advances Alzheimer's Vaccine to Phase Ib/IIa Study
- AC Immune (ACIU) advances its Alzheimer's disease vaccine, ACI-35.030, to phase Ib/IIa study.
- 07/17/2020
|
Principia Sanofi Rumors, And Other News: The Good, Bad And Ugly Of Biopharma
- Principia up on Sanofi interest rumors. Qiagen N.V.
- 07/17/2020
|
The Daily Biotech Pulse: 2 IPOs, Nabriva Pneumonia Drug Gets Canadian Regulatory Nod, PhaseBio Doses First COVID-19 Trial Patient
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 16) * AC Immune SA (NASDAQ: ACIU) ( announced clinical trial update for its Alzheimer's vaccine candidate) * argenx SE - ADR (NASDAQ: ARGX) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * Castle Biosciences Inc (NASDAQ: CSTL) * Dynavax Technologies Corporation (NASDAQ: DVAX)(announced a collaboration with Mt. Sinai to develop a universal influenza vaccine candidate with CpG1018 adjuvant) * Heat Biologics Inc (NASDAQ: HTBX) * Novavax, Inc. (NASDAQ: NVAX) * Qiagen NV (NYSE: QGEN)( Thermo Fisher Scientific Inc. (NYSE: TMO) announced a sweetened offer to buy the company) * Quest Diagnostics Inc (NYSE: DGX) * Otonomy Inc (NASDAQ: OTIC) * Principia Biopharma Inc (NASDAQ: PRNB)(reacted to buyout rumors) * Relay Therapeutics Inc (NASDAQ: RLAY) (jumped 75.25% on its debut) * Sanofi SA (NASDAQ: SNY) (Bloomberg reported the French biotech is on a lookout to buy biotech companies, including Principia) * TIZIANA LF SCIE/S ADR (NASDAQ: TLSA) * West Pharmaceutical Services Inc. (NYSE: WST)Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 16) * Avidity Biosciences Inc (NASDAQ: RNA) * Legend Biotech Corp (NASDAQ: LEGN) * Nkarta Inc (NASDAQ: NKTX) (IPOed last Friday) * Repare Therapeutics Inc (NASDAQ: RPTX) * Tricida Inc (NASDAQ: TCDA) ( received a letter from FDA citing deficiencies in its NDA for the approval of metabolic acidosis treatment candidate)Stocks In Focus PhaseBio Doses First Patient In Potentially Pivotal Trial of PB1046 For COVID-19 PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) said it has dosed the first patient in a potentially pivotal Phase 2 clinical trial, dubbed VANGARD, to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome, or ARDS.PB1046 is a novel, once-weekly, subcutaneously-injected VIP receptor agonist that targets VPAC receptors in the cardiovascular, pulmonary and immune systems, having anti-inflammatory, antifibrotic and potent bronchodilatory and immunomodulatory effects in the respiratory system.The stock advanced 10.21% to $5.18 in after-hours trading.Applied DNA Reports Positive Preclinical Data For DNA Vaccine Candidates Applied DNA Sciences Inc (NASDAQ: APDN) announced linear-DNA forms of COVID-19 vaccine candidates under development by partner Takis Biotech and manufactured by it yielded strong antibody and T-cell responses even at very low doses of linear DNA, raising the potential of effective dosing empowering global utility.In premarket trading Friday, Applied DNA shares were jumping 79.09% to $16.10.Puma Biotech Announces Regulatory Nod For Breast Cancer Drug In MalaysiaPuma Biotechnology Inc (NASDAQ: PBYI) said its licensing partner Specialised Therapeutics Asia has received marketing approval of Nerlynx in Malaysia from the Drug Control Agency, under Malaysia's Ministry of Health.Nerlynx is indicated for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy.In after-hours trading, the stock gained 3.89% to $10.15.Nabriva's Community-acquired Pneumonia Drug Approved In Canada Nabriva Therapeutics PLC - ADR (NASDAQ: NBRV) said its partner, Sunovion Pharmaceuticals Canada Inc., has received approval from Health Canada to market oral and intravenous formulations of Xenleta for the treatment of community-acquired pneumonia in adults.The stock jumped 29.76% to $1.09 in after-hours trading.ASLAN to Transfer Primary Listing to Nasdaq ASLAN PHARMACEU/ADR (NASDAQ: ASLN) said it has made further progress toward a primary listing on the Nasdaq and the receipt of a Notice of Delisting from the Taipei Exchange, in an expected step in the TPEx delisting process.The company also said it will retain its listing of ADSs on Nasdaq and existing holders of ADS do not need to take any action as a result of this announcement.On The Radar IPOs Pandion Therapeutics, Inc., a clinical-stage biotech developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune disease, said it has priced its upsized initial public offering, or IPO, of 7.5 million shares at $18 per share to raise gross proceeds of $135 million. The company earlier estimated the pricing to be between $16 and $18. The shares will begin trading on the Nasdaq under the ticker symbol PAND.LX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, priced its IPO of 8.5 million shares at $19 per share compared to the estimated price range of $15-$17.The company expects to raise gross proceeds of $161.5 million from the offering. The shares will begin trading on the Nasdaq under the ticker symbol ALXO.Renalytix AI plc, an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease, priced its global offering of an aggregate of 11 million shares. The offering is expected to raise gross proceeds of $74.3 million.See more from Benzinga * The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent * The Daily Biotech Pulse: Blueprint, Roche Ink .7B Cancer Drug Collaboration, INmune's Positive Alzheimer's Readout, Edwards, Abbott Settle Patent Lawsuits(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 07/17/2020
|
Here's Why AC Immune Jumped Higher Today
- Investors are excited about the company advancing its Alzheimer's disease vaccine, but caution is warranted.
- 07/16/2020
|
AC Immune Stock Catapults To Two-Year High On Alzheimer's News
- AC Immune surged in massive volume Thursday after the small biotech company began dosing patients with an Alzheimer's treatment. The drug will be tested over 48 weeks in early-stage patients.
- 07/16/2020
|
AC Immune Explodes 56% In Pre-Market On Alzheimer Study Initiation
- Shares in AC Immune (ACIU) are surging 56% in Thursday’s pre-market trading after the biopharma announced the initiation of the second highest dosing group in the its Phase 1b/2a clinical trial evaluating ACI-35.030 for the treatment of Alzheimer’s disease (AD).The decision to advance to the higher dosing group follows encouraging interim safety, tolerability and immunogenicity results from the initial dosing group.Immunization with anti-Tau vaccines has become an important strategy for the treatment of AD and other neurodegenerative diseases characterized by Tau pathology, says AC Immune.ACI-35.030, which is being developed in collaboration with Johnson & Johnson’s (JNJ) Janssen Pharmaceuticals, Inc., is the first AD vaccine candidate designed to generate a specific antibody response against pathologic phospho-Tau (pTau) proteins in the brain. This can potentially reduce the spread and seeding of Tau pathology throughout the brain.Prof. Andrea Pfeifer, CEO of AC Immune SA, commented: “The fact that ACI-35.030 shows encouraging safety and immunogenicity at the lowest dose in this elderly patient population is highly meaningful and we look forward to quickly enrolling this next dosing group.”She continued: “Tau-targeted approaches may have a much broader therapeutic window to potentially disrupt, slow or prevent disease progression at both early and advanced disease stages. Pathological pTau occurs early in the disease process, years before accumulation of Tau deposits. Therefore, our pTau-targeting approach holds significant promise for the treatment of AD at different disease stages.”This Phase 1b/2a trial is a randomized, multicenter, double-blind, placebo-controlled clinical study with a primary objective to assess the safety, tolerability and immunogenicity of different doses of ACI-35.030 over a 48-week treatment phase in 24 patients with early AD. Other endpoints will assess clinical and cognitive parameters as well as additional immunogenicity and safety parameters.Alzheimer’s disease is a devastating neurodegenerative disease of the central nervous system which is responsible for 60-80% of all cases of dementia and progressively destroys the cognitive abilities of those who develop the disease.HC Wainwright analyst Andrew Fein has a buy rating on ACIU with an $11 price target (53% upside potential). “We believe a disconnect remains for fully appreciating AC Immune’s AD platform as reflected by its market capitalization, which we believe can be realized as upside following potentially validating data anticipated later this year” he commented on July 9. (See ACIU stock analysis on TipRanks)Related News: Boston Scientific Mulls Billion-Dollar Snake Venom Sale- Report Becton, Dickinson Score Fed Contract For Covid-19 Rapid Test Systems Akebia Initiates Vadadustat Study In Covid-19 Patients More recent articles from Smarter Analyst: * Tesla Car Registrations In California Sink 48% in Q2 - Report * Novartis To Sell Covid-19 Drugs At Zero-Profit To Low-Income Countries * Zoom Launches Its Own Video-Conferencing Hardware For In-Home Use * Google Shifts Business Apps To Accommodate Stay-At-Home Workforce
- 07/16/2020
|
AC Immune Advances phospho-Tau Alzheimer’s Vaccine in Phase 1b/2a Study
- Interim data confirm the promising safety, tolerability and Tau-specific immunogenicity observed in the previous clinical study ACI-35.030 is a clinical stage vaccine generated.
- 07/16/2020
|
Tau-PET Tracer PI-2620 Could Set New Standards for an Improved Diagnosis of Progressive Supranuclear Palsy
- BERLIN and LAUSANNE, Switzerland, July 07, 2020 -- Life Molecular Imaging and AC Immune SA (NASDAQ: ACIU) announce the publication of clinical data of the investigational.
- 07/07/2020
|
How Much Of AC Immune SA (NASDAQ:ACIU) Do Insiders Own?
- A look at the shareholders of AC Immune SA (NASDAQ:ACIU) can tell us which group is most powerful. Institutions often...
- 07/07/2020
|
Hedge Funds Have Never Been This Bullish On AC Immune SA (ACIU)
- The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]
- 07/04/2020
|
AC Immune Announces Results of Annual General Meeting
- AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, announced AC Immune shareholders approved all of the resolutions as proposed by the Board of Directors at today's Annual General Meeting (AGM) in Lausanne. At the AGM, shareholders re-elected Douglas Williams, Martin Velasco, Peter Bollmann, Andrea Pfeifer, Thomas Graney, Werner Lanthaler and Roy Twyman to their positions on the Board of Directors. Douglas Williams and Martin Velasco will continue to serve as Chairman and Vice-Chairman of the Board, respectively.
- 06/26/2020
|
AC Immune CEO to Showcase Novel Target Programs at UBS Global Healthcare Conference
- LAUSANNE, Switzerland, May 15, 2020 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.
- 05/15/2020
|
AC Immune SA (NASDAQ:ACIU) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
- As you might know, AC Immune SA (NASDAQ:ACIU) just kicked off its latest quarterly results with some very strong...
- 05/06/2020
|
AC Immune (ACIU) Reports Q1 Loss, Tops Revenue Estimates
- AC Immune (ACIU) delivered earnings and revenue surprises of 47.06% and 24.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/04/2020
|
AC Immune Reports Q1 2020 Financial Results and Provides Business Update
- On track to meet the five clinical milestones expected in 2020 with no modifying guidance as a result of Covid-19Ongoing strong financial position with CHF 277.9 million in.
- 05/04/2020
|
Axsome Shares Jump 25% on Alzheimer's Study Results
- Clinical trial of AX-05 showed drug reduces patient agitation Continue reading...
- 04/28/2020
|
Axsome Shares Jump 25% on Alzheimer€™s Study Results
- Axsome Shares Jump 25% on Alzheimer’s Study Results, Stocks: AXSM,LLY,RHHBY,ACIU,MOR,ESALY,BIIB, release date:Apr 27, 2020
- 04/28/2020
|
Head to Head Survey: Eli Lilly And Co (NYSE:LLY) versus Syros Pharmaceuticals (NYSE:SYRS)
- Eli Lilly And Co (NYSE:LLY) and Syros Pharmaceuticals (NASDAQ:SYRS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends. Profitability This table compares Eli Lilly And Co and Syros Pharmaceuticals’ net margins, return […]
- 04/25/2020
|
Lilly Reports Strong First-Quarter Financial Results, Adjusts EPS Guidance
- Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2020.
- 04/23/2020
|
Neurology at Forefront of FDA’s Complex Innovative Trial Design Pilot
- The coronavirus pandemic has frozen many clinical trials and forced others to adapt in the face of overwhelmed healthcare systems around the world. When
- 04/16/2020
|
Newsflash: AC Immune SA (NASDAQ:ACIU) Analysts Have Been Trimming Their Revenue Forecasts
- The analysts covering AC Immune SA (NASDAQ:ACIU) delivered a dose of negativity to shareholders today, by making a...
- 04/04/2020
|
AC Immune Presents the Latest Preclinical Data on Novel Drug Targets for Neurodegenerative Diseases
- Seven presentations by AC Immune and its partners at AAT-AD/PD™ New data on early-stage TDP-43 and alpha-synuclein therapeutic and diagnostic candidates A lead.
- 04/02/2020
|
Analysts Offer Insights on Healthcare Companies: ObsEva SA (OBSV), AC Immune SA (ACIU) and Co-Diagnostics (CODX)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ObsEva SA (OBSV), AC Immune SA (ACIU) and Co-Diagnostics
- 04/01/2020
|
Analysts Offer Insights on Healthcare Companies: ObsEva SA (NASDAQ: OBSV), AC Immune SA (NASDAQ: ACIU) and Co-Diagnostics (NASDAQ: CODX)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ObsEva SA
- 04/01/2020
|
AC Immune Reports Full-Year 2019 Financial Results and Provides 2020 R&D Outlook
- Ongoing strong financial position with CHF 288.6 million in cash, ensuring the Company is fully financed through Q1 2024, excluding potential incoming milestonesReceived CHF 110.
- 03/30/2020
|
Company News for Mar 24, 2020
- Companies in the news are: HAS, PCG, WTRH, ACIU
- 03/24/2020
|
AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer™ Tau Partnership
- AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced that it will receive a second milestone payment of CHF 10 million from Eli Lilly and Company on or before March 31, 2020 related to development progress in the small molecule Morphomer™ Tau aggregation inhibitor program. The multi-year collaboration agreement between Lilly and AC Immune was originally announced in December 2018 and focuses on the broad development of Morphomer™ Tau aggregation inhibitors for Alzheimer’s disease (AD) and other neurodegenerative diseases.
- 03/23/2020
|
Contrasting AC Immune (NASDAQ:ACIU) & Takeda Pharmaceutical (NASDAQ:TKPYY)
- AC Immune (NASDAQ:ACIU) and Takeda Pharmaceutical (OTCMKTS:TKPYY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership. Analyst Ratings This is a breakdown of current ratings for AC Immune and Takeda Pharmaceutical, as […]
- 03/21/2020
|
Internationally Renowned Neurologist Dr. Juan Fortea Joins AC Immune’s Clinical Advisory Board
- LAUSANNE, Switzerland, March 20, 2020 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative.
- 03/20/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) * Biomerica, Inc. (NASDAQ: BMRA)( announced commencement of international shipment of rapid COVID-19 test) * BioNTech SE - ADR (NASDAQ: BNTX) *
- 03/19/2020
|
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) * BioNTech SE - ADR (NASDAQ: BNTX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN) ( Updated on its COVID-19 treatment development plan)Down In The
- 03/18/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced efforts to develop a vaccine for COVID-19) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)Down In The Dumps
- 03/17/2020
|
Guardant Health (GH) in Focus: Stock Moves 6.5% Higher
- Guardant Health (GH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- 03/13/2020
|
Guardant Health (GH) in Focus: Stock Moves 6.5% Higher
- Guardant Health (GH) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- 03/13/2020
|
AC Immune to Present New Data Demonstrating the Depth of its Neurodegenerative Programs at the Upcoming Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting
- LAUSANNE, Switzerland, March 05, 2020 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, announced today that four new data presentations.
- 03/05/2020
|
Is AC Immune SA's (NASDAQ:ACIU) CEO Pay Justified?
- Andrea Pfeifer is the CEO of AC Immune SA (NASDAQ:ACIU). This analysis aims first to contrast CEO compensation with...
- 02/24/2020
|
Analysts Offer Insights on Healthcare Companies: AC Immune SA (ACIU), Autolus Therapeutics (AUTL) and AquaBounty Technologies (AQB)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AC Immune SA (ACIU), Autolus Therapeutics (AUTL) and
- 02/18/2020
|
Top Ranked Momentum Stocks to Buy for January 30th
- Top Ranked Momentum Stocks to Buy for January 30th
- 01/30/2020
|
Top Ranked Momentum Stocks to Buy for January 30th
- Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 30th.
- 01/30/2020
|
Lilly Reports Strong Fourth-Quarter and Full-Year 2019 Financial Results, Updates 2020 Guidance for Pending Dermira Acquisition
- Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2019.
- 01/30/2020
|
AC Immune SA (NASDAQ:ACIU) Has A ROE Of 17%
- One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- 12/24/2019
|
Did Hedge Funds Drop The Ball On AC Immune SA (ACIU) ?
- Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
- 12/16/2019
|
AC Immune to Present at Jefferies 2019 London Healthcare Conference
- LAUSANNE, Switzerland, Nov. 14, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative.
- 11/14/2019
|
AC Immune Q3 2019 Financial Results and Business Update
- CHF 32 Million in Milestone Revenues Multiple Upcoming Catalysts Execution Across Clinical and Preclinical Neurodegenerative Development Pipeline LAUSANNE, Switzerland,.
- 11/13/2019
|
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
- Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.
- 11/11/2019
|
Linde (LIN) to Report Q3 Earnings: What's in the Cards?
- Favorable industrial production in the United States is likely to have favored Linde's (LIN) Q3 earnings.
- 11/08/2019
|
AC Immune Hosts Key Opinion Leader Event: ‘Untangling’ Tau Pathology to Treat Alzheimer’s and Neurodegenerative Diseases
- Company Provides Key Updates on Tau Pipeline Candidates LAUSANNE, Switzerland, Nov. 06, 2019 -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical.
- 11/06/2019
|
